Drug Trial Radar · NCT02679573
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Last checked: Nov 20, 2026Latest source record: Feb 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
860
Actual
Start
Dec 14, 2016
Primary completion
Jul 31, 2018
Study completion Aug 7, 2018
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
Conditions
- Community Acquired Bacterial Pneumonia
Interventions
DelafloxacinDrug
Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
MoxifloxacinDrug
Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
LinezolidDrug
Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical ResponseTime frame: 96 (+/- 24) hours after the first dose of study drug
Locations
90 sites in 18 countries. Site status is shown where the registry gives one.
Melinta 306 Study Site
Montgomery, Alabama
Melinta 306 Study Site
Newark, Delaware
Melinta 306 Study Site
Coral Gables, Florida
Melinta 306 Study Site
DeBary, Florida
Melinta 306 Study Site
DeLand, Florida
Melinta 306 Study Site
Fort Myers, Florida
Melinta 306 Study Site
Miami, Florida
Melinta 306 Study Site
Miami, Florida
Melinta 306 Study Site
Louisville, Kentucky
Melinta 306 Study Site
Natchitoches, Louisiana
Melinta 306 Study Site
Baltimore, Maryland
Melinta 306 Study Site
Boston, Massachusetts
Melinta 306 Study Site
Burlington, Massachusetts
Melinta 306 Study Site
Saint Paul, Minnesota
Melinta 306 Study Site
St Louis, Missouri
Melinta 306 Study Site
Butte, Montana
Melinta 306 Study Site
Omaha, Nebraska
Melinta 306 Study Site
Newark, New Jersey
Melinta 306 Study Site
Buffalo, New York
Melinta 306 Study Site
Charlotte, North Carolina
Melinta 306 Study Site
Cleveland, Ohio
Melinta 306 Study Site
Dayton, Ohio
Melinta 306 Study Site
Rapid City, South Dakota
Melinta 306 Study Site
Franklin, Tennessee
Melinta 306 Study Site
Corsicana, Texas
Melinta 306 Study Site
Buenos Aires, Argentina
Melinta 306 Study Site
Córdoba, Argentina
Melinta 306 Study Site
La Plata, Argentina
Melinta 306 Study Site
Pleven, Bulgaria
Melinta 306 Study Site
Rousse, Bulgaria
Melinta 306 Study Site
Sofia, Bulgaria
Melinta 306 Study Site
Stara Zagora, Bulgaria
Melinta 306 Study Site
Barranquilla, Colombia
Melinta 306 Study Site
Cali, Colombia
Melinta 306 Study Site
Manizales, Colombia
Melinta 306 Study Site
Medellín, Colombia
Melinta 306 Study Site
Quindío, Colombia
Melinta 306 Study Site
Santo Domingo, Dominican Republic
Melinta 306 Study Site
Tbilisi, Georgia
Melinta 306 Study Site
Leverkusen, Germany
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.